一项评估PF-07994525在晚期癌症患者中的开放性研究
一项评估PF-07994525在晚期恶性肿瘤受试者中疗效的开放标签1期研究
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Pfizer CT.gov Call Center
- 电话号码:1-800-718-1021
- 邮箱:ClinicalTrials.gov_Inquiries@pfizer.com
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 5G2
- 招聘中
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V 5C2
- 尚未招聘
- Juravinski Cancer Centre
-
Toronto、Ontario、加拿大、M5G2M9
- 招聘中
- University Health Network- Princess Margaret Cancer Centre
-
-
-
-
Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- Colorado Blood Cancer Institute
-
Denver、Colorado、美国、80218
- 招聘中
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven、Connecticut、美国、06511
- 招聘中
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven、Connecticut、美国、06510
- 招聘中
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven、Connecticut、美国、06510
- 招聘中
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven、Connecticut、美国、06511
- 招聘中
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven、Connecticut、美国、06473
- 招聘中
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables、Florida、美国、33146
- 招聘中
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs、Florida、美国、33065
- 招聘中
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach、Florida、美国、33442
- 招聘中
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral、Florida、美国、33166
- 招聘中
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood、Florida、美国、33021
- 招聘中
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami、Florida、美国、33136
- 招聘中
- Sylvester Comprehensive Cancer Center
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Hospital and Clinics
-
Miami、Florida、美国、33176
- 招聘中
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami、Florida、美国、33181
- 招聘中
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation、Florida、美国、33324
- 招聘中
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta、Georgia、美国、30308
- 招聘中
- Emory University Hospital Midtown
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University Hospital
-
Atlanta、Georgia、美国、30322
- 招聘中
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- The James Cancer Hospital and Solove Research Institute
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University Hospitals
-
Columbus、Ohio、美国、43210
- 招聘中
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute - Pharmacy
-
Nashville、Tennessee、美国、37203
- 招聘中
- Tristar BMT
-
Nashville、Tennessee、美国、37203
- 招聘中
- SCRI Oncology Partners
-
Nashville、Tennessee、美国、37203
- 招聘中
- TriStar Centennial Medical center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
实验性的:Part 2
Monotherapy Dose Escalation |
Oral administration |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
大体时间:Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
根据研究者判断,依据国际骨髓瘤工作组(IMWG)疗效标准评估的客观缓解率(ORR)。
大体时间:从基线期至首次记录疾病进展、死亡或开始新的抗癌治疗之日(约2年)
|
从基线期至首次记录疾病进展、死亡或开始新的抗癌治疗之日(约2年)
|
|
|
根据研究者评估,依据国际骨髓瘤工作组(IMWG)疗效标准判定的完全缓解率(CRR)。
大体时间:从基线到首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
从基线到首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
|
|
根据研究者确定的IMWG缓解时间(TTR)
大体时间:从基线期至首次记录疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
从基线期至首次记录疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
|
|
研究者根据国际骨髓瘤工作组(IMWG)标准确定的有效持续时间(DOR)
大体时间:从基线期至首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
从基线期至首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
|
|
研究者根据IMWG标准判定的完全缓解持续时间 (DOCR)
大体时间:从基线期至首次记录到疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
从基线期至首次记录到疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
|
|
研究者根据IMWG标准判定的无进展生存期(PFS)
大体时间:从基线期至首次记录疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
从基线期至首次记录疾病进展、死亡或开始新抗癌治疗的日期(约2年)
|
|
|
总生存期 (OS)
大体时间:基线至首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
基线至首次记录疾病进展、死亡或开始新的抗癌治疗的日期(约2年)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
大体时间:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- C6331001
- KAT2i (其他标识符:Alias Study Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.